Treatable Diseases and Scientific Evidence
Breast Cancer
Cabula C et al. (2015)
In 125 patients, electrochemotherapy achieved ~89% objective response with 73% complete regressions of cutaneous breast metastases. The study showed high efficacy even in heavily pretreated or radioresistant lesions.
It supports electrochemotherapy as a non-invasive local tumor control option. Best outcomes were seen in smaller and non-ulcerated tumors.
Grischke EM et al. (2017)
Electrochemotherapy was used as an adjunct to systemic therapy in chest wall breast cancer recurrences. The approach helped enhance local control while reducing tumor burden. Treatment was well-tolerated and integrated effectively into combination protocols. It offers value especially for patients unfit for further surgery or radiotherapy.
Bourke MG et al. (2017)
This 10-year audit confirmed durable tumor control in cutaneous breast metastases with electrochemotherapy. Smaller lesions had superior outcomes, and no serious adverse events occurred.
The data supports early intervention to maximize treatment response. Electrochemotherapy is validated as a safe and effective long-term strategy.
Matthiessen LW et al. (2018)
Data from the INSPECT database showed a 71% overall response in breast skin metastases. Electrochemotherapy provided fast local control with minimal invasiveness.
It proved especially useful as a palliative and cosmetically favorable option. Patients tolerated the treatment well, with low toxicity levels reported.
Ferioli M et al. (2020)
A systematic review confirmed high efficacy of electrochemotherapy in breast skin metastases. One- and three-year progression-free survival were 86% and 81% respectively.
The treatment was consistent across varied clinical settings and tumor burdens. Its safety and long-term results support broader clinical adoption.
Melanoma
Kunte C et al. (2017)
A large prospective cohort showed 74% overall and 58% complete response in skin metastases. Electrochemotherapy was effective in both first-line and recurrent cases.
Response durability and safety were confirmed in a multi-country trial. This supports its use in both palliative and curative contexts.
Heppt MV et al. (2016)
Electrochemotherapy combined with checkpoint inhibitors improved both local and systemic control. The approach demonstrated synergy without added toxicity.
It enabled tumor regression in otherwise refractory lesions. Data supports combination strategies in metastatic melanoma.
Theurich S et al. (2016)
Adding electrochemotherapy to ipilimumab improved survival in advanced melanoma. Local tumor burden was reduced while immune response was preserved.
Combination therapy was feasible and well tolerated. Electrochemotherapy may enhance immunotherapy efficacy.
Goggins CA et al. (2019)
A focused review confirmed that combining electrochemotherapy with immunotherapy improves outcomes. The approach reduced tumor size while maintaining immune activity.
Toxicity remained low and controllable in metastatic melanoma. It represents a promising multimodal approach.
Fabrizio T et al. (2020)
Used preoperatively, electrochemotherapy downsized tumors for easier excision. Postoperative healing and cosmetic results were favorable.
It supported neoadjuvant planning in cutaneous melanoma. The study confirmed functional and surgical advantages.
Clover AJP et al. (2020)
Analysis of 2,482 lesions in 987 patients showed ~80% response rate to electrochemotherapy. Consistent efficacy was observed across centers and indications.
Treatment had a favorable safety and complication profile. This supports widespread use in cutaneous metastases.
Case Report
A large bleeding lymph node metastasis was successfully controlled using electrochemotherapy. Bleeding stopped immediately and the lesion reduced in size.
This shows fast-acting palliative potential in emergency settings. Treatment improved patient comfort and local control.
Vulvar Carcinoma
Perrone AM et al. (2018)
Electrochemotherapy used before surgery reduced tumor size in vulvar cancer. Most patients achieved ≥50% shrinkage, allowing less aggressive resection.
Treatment was well-tolerated and anatomy-preserving. It supports neoadjuvant use in locally advanced disease.
Perrone AM et al. (2019)
The multicenter ELECHTRA study showed >70% local control in recurrent vulvar carcinoma. Electrochemotherapy also provided significant pain relief and quality-of-life benefits.
No major complications were observed in this elderly cohort. It proved safe and effective for palliative management.
Head & Neck Malignancies
Gargiulo M et al. (2012)
Among 25 patients with non-melanoma tumors, electrochemotherapy yielded a 100% response at six weeks. Complete response was achieved in 72%, with sustained control after 18 months.
Treatment preserved organ function and showed no local recurrence. It offers a viable approach in delicate anatomical areas.
Bertino G et al. (2016)
The EURECA project reported 97% response in basal cell carcinoma and 74% in other tumors. Electrochemotherapy was well-tolerated with high local efficacy.
It minimized need for surgery or radiation in head and neck cancers. Treatment was delivered safely even in elderly or fragile patients.
Plaschke CC et al. (2017)
In mucosal cancers, the study showed 56% objective response after electrochemotherapy. Minimal side effects were reported, even in anatomically sensitive areas.
The treatment preserved surrounding function and appearance. Electrochemotherapy proved feasible as a non-surgical solution.
Gargiulo M et al. (2018)
Long-term tumor control was observed in lower lip squamous cell carcinoma cases. Electrochemotherapy preserved oral function and delivered excellent cosmetic results.
Tumor shrinkage allowed for conservative management without extensive resection. The therapy is ideal for functional and aesthetic preservation.
Kis EG et al. (2019)
Electrochemotherapy treated periocular basal cell carcinomas with high control rates. Visual and eyelid function was preserved across treated patients.
It showed high local efficacy and was well tolerated with minimal side effects. This supports its use in cosmetically and functionally complex locations.
Bonadies A et al. (2019)
In 33 patients, 82% had complete response after electrochemotherapy of head/neck skin lesions. Aesthetic results were graded excellent in 96% of treated scars.
The study confirmed both clinical and cosmetic benefits of the approach. Electrochemotherapy was a safe and patient-friendly treatment.
Non-Melanoma Skin Cancers
Campana LG et al. (2017)
A 10-year experience treating basal cell carcinoma showed 72.5% complete response after one electrochemotherapy session. This increased to 85% with a second session, confirming the treatment’s high efficacy.
Best outcomes were seen in small, non-ulcerated lesions. Electrochemotherapy offered a safe, repeatable alternative to surgery.
Di Monta G et al. (2017)
In 22 cases of advanced squamous cell carcinoma, electrochemotherapy achieved an 81.8% objective response. Treatment showed early tumor necrosis and acceptable tolerance.
Most patients experienced rapid improvement in local symptoms. It proved especially useful for palliative local tumor control.
Gargiulo M et al. (2018)
Electrochemotherapy provided sustained control in lower lip squamous cell carcinoma. The approach preserved oral function and facial symmetry.
Cosmetic outcomes were excellent, with minimal post-treatment fibrosis. It supports organ-sparing care in complex aesthetic zones.
Clover AJP et al. (2020)
A randomized trial comparing electrochemotherapy and surgery for primary BCC showed equivalent control. Cosmetic outcomes were superior in the electrochemotherapy group.
Long-term results confirmed its viability as a first-line option. The study supports non-surgical treatment for select patients.
Fabrizio T et al. (2020)
Electrochemotherapy used neoadjuvantly improved operability in skin cancer cases. Tumor shrinkage simplified excision and enhanced reconstruction.
This strategy proved helpful for large or high-risk lesions. The treatment was safe, localized, and well-integrated with surgery.
Clover AJP et al. (2020)
Data from 2,482 lesions across Europe confirmed ~80% response to electrochemotherapy. The approach was consistent across skin cancer subtypes and sizes.
Safety profile remained favorable even in elderly patients. This validated its role in routine oncologic dermatology care.
Liver Tumors
Coletti L et al. (2017)
In patients with colorectal liver metastases, electrochemotherapy was safe during open surgery. More than 50% of treated lesions had complete response at 30 days.
Patients had minimal complications and recovered well. This confirms feasibility in deep visceral tumors.
Edhemovic I et al. (2020)
In a Phase II trial, electrochemotherapy achieved 63% complete response in 84 metastases. Median survival was 29 months, and tumors <3 cm responded best.
The approach allowed continued systemic therapy. It shows promise for otherwise unresectable liver lesions.
Tarantino L et al. (2017)
Electrochemotherapy treated portal vein tumor thrombosis in cirrhotic HCC patients. The procedure was percutaneous, image-guided, and well tolerated.
It provided a non-surgical option in high-risk vascular disease. Tumor stabilization was observed without liver function decline.
Tarantino L et al. (2018)
Patients with cholangiocarcinoma at the hepatic hilum received electrochemotherapy safely. Tumor control was achieved despite the complex location.
Minimal toxicity was reported in this small feasibility study. It offers hope in inoperable biliary tract tumors.
Djokic M et al. (2018)
Electrochemotherapy was applied to hepatocellular carcinoma with good local effect. Most patients were unsuitable for thermal ablation.
Treatment showed promising tumor response and liver preservation. It supports further research in HCC populations.
Cornelis FH et al. (2019)
Image-guided electrochemotherapy treated a renal cell carcinoma liver metastasis. Local tumor control was achieved without complications.
The technique combined well with other imaging modalities. This case shows its application beyond colorectal primaries.
Pancreatic Cancer
Granata V et al. (2015)
A Phase I/II study showed electrochemotherapy was feasible and safe during open surgery. No major adverse events were reported in patients with locally advanced tumors.
MRI scans confirmed early tumor response and reduced enhancement. This supports its potential for deep visceral tumor control.
Granata V et al. (2017)
Imaging after electrochemotherapy in pancreatic cancer showed promising local response. 100% of cases had partial response by Choi criteria, and 60% by PET (PERCIST).
The results highlight early efficacy in inoperable or borderline lesions. Functional imaging proved useful in treatment assessment.
Gastrointestinal Cancers
Snoj M et al. (2005)
A case of anorectal melanoma was treated with electrochemotherapy and conservative surgery. Sphincter function was preserved and no recurrence was observed.
The therapy enabled a less invasive approach with good control. It shows potential in sensitive anatomical areas.
Ferioli M et al. (2020)
A patient with recurrent anorectal adenocarcinoma achieved full local response post-electrochemotherapy. One-year follow-up showed no evidence of disease.
Treatment was performed safely with maintained function. This case supports its use as a salvage option.
Farricha V et al. (2020)
Among eight patients with primary or recurrent anorectal melanoma, 75% achieved complete response. Electrochemotherapy controlled bleeding in all cases with minimal toxicity.
One-year survival reached 87.5%, despite advanced presentation. Results suggest strong efficacy in this rare malignancy.
Sarcoma & soft tissue cancers
Campana LG et al. (2014)
In a Phase II study of 42 patients, electrochemotherapy achieved 65% objective response in soft tissue sarcomas. Complete response occurred in 38% of lesions, with durable local control. Treatment was well-tolerated even in advanced disease.
It supports its role in non-resectable or borderline tumors.
Simioni A et al. (2020)
Using variable-geometry long-needle electrodes, electrochemotherapy treated deep soft tissue tumors.
70% had objective metabolic response, with 40% achieving complete PET response. Local control exceeded 12 months in most cases.
This method expanded access to larger or irregular tumors.
Where can you find a clinic with ECT?
Country
Clinic Name
Street name goes here 15, Vigo 3550-399 Vigo
Country
Clinic Name
Street name goes here 15, Vigo 3550-399 Vigo
Country
Clinic Name
Street name goes here 15, Vigo 3550-399 Vigo
Country
Clinic Name
Street name goes here 15, Vigo 3550-399 Vigo
Country
Clinic Name
Street name goes here 15, Vigo 3550-399 Vigo
Country
Clinic Name
Street name goes here 15, Vigo 3550-399 Vigo
Country
Clinic Name
Street name goes here 15, Vigo 3550-399 Vigo
Country
Clinic Name
Street name goes here 15, Vigo 3550-399 Vigo